James Kerwin

James Kerwin is an accomplished executive with extensive experience in the pharmaceutical and biotechnology industries. Currently serving as Executive Director at Daiichi Sankyo US since February 2022, James previously held prominent roles such as Sr. Director of Global Oncology Business Strategy and Analytics. Prior experience includes positions at Genmab, Bristol-Myers Squibb, Celgene, and Daiichi Sankyo, with a focus on business insights, analytics, and development across various therapeutic areas. James's career began as a Sr. Financial Analyst at Schering-Plough, and foundations in finance and international business were established through academic qualifications from Seton Hall University and Fairleigh Dickinson University.